NASDAQ: ABIO Sharing Pricing Rebounds Up By 68.7%: Will It Be Consistent?


In the previous trading session, ARCA Biopharma, Inc (NASDAQ: ABIO) encountered 4041k shares changing hands with a beta value of 3.1. For the past couple of weeks, ABIO shares were low which might be because of the current challenging situations. However, the company shares recently went up high by 68.7%. As a result, many marketers are hoping that ABIO share pricing will hold such high value in the coming time as well. However, traders need to keep informed about what is happening every day!

ARCA Biopharma, Inc Company Profile:

ARCA Biopharma, Inc (NASDAQ: ABIO at is a biopharmaceutical company that conducts researches and development of genetically-targeted therapies for different cardiovascular diseases. The lead product of ABIO is Gencaro (Bucindolol hydrochloride) which is an investigational and pharmacologically unique beta-blocker and mild vasodilator. However, it is still in the development stage.

ABIO current stock price:

ABIO’s stock was trading at $3.36 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then its stock value increased by 110.1% and is trading now at $7.06(as of 19th July 2020).

NASDAQ: ABIO reported earnings per share (EPS) for the quarter are $0.83beating the Zacks’ consensus estimate of ($2.04 by $1.21). The biopharmaceutical company has generated $0.00 earnings per share over the last year. The next earning date is scheduled to release on Thursday, 6th August of 2020.

ABIO profitability & price target:

Profit margin is a useful ratio and can help provide an insight of a variety of aspects of financial performance. The profit margin may also indicate certain things about the company’s ability to manage its expenses.  NASDAQ: ABIO has a market capitalization of $24.00 million and net income (for the most recent Fiscal year) is $-5.48 million. Plus, its Return to Equity and Return on Assets are -64.42 % and -56.56% respectively.

Research analysts have issued 1-year price targets which range from $2.21to $22.00. On average, they expect the share price to reach $15.00 in the next year which suggests a possible upside of 112.46%. The Beta factor describes the movement in a stock’s return to the market return and also provides a measure of the systematic risk of security as compared to the whole market. Its Beta value is 3.1 (which is greater than one) indicates that the security will move with more force than the market.

What to expect next?

Marketers should keep an eye on the latest news related to ABIO stock market pricing every day. ABIO got coverage by media recently indicating to affect the company’s share price in the next several days. However, it is not certain about what will happen next to invest in stock app! Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.